ACE Technology Guidances communicate recommendations from the MOH Drug Advisory Committee or the MOH Medical Technology Advisory Committee on the funding status and appropriate use of drugs, vaccines or medical technologies that have been evaluated by ACE. The guidances also include the Committee’s rationale for the funding recommendations, and key clinical and economic evidence which informed their deliberations. Plain English Summaries (PES) to explain ACE Technology Guidances are available for patients and the public.

Published on 04 Jun 2024
Last Updated on 04 Jun 2024
A- A+
Guidance Recommendations
The Ministry of Health’s Drug Advisory Committee has not recommended vortioxetine for inclusion on the MOH List of Subsidised Drugs for treatment of depression. This decision was due to unfavourable cost effectiveness compared with subsidised alternative treatments, based on the price proposal from the manufacturer.

Vortioxetine for treatment of depression (Published 4 Jun 24)